Funded Startups in Watertown
Across these 30 Watertown entries (newest round date descending), disclosed funding is dominated by one outlier: Affini-T Therapeutics’ $175M disclosed ven…
Across these 30 Watertown entries (newest round date descending), disclosed funding is dominated by one outlier: Affini-T Therapeutics’ $175M disclosed venture round on 2022-03-22, which sits well above the next-largest disclosed amounts (e.g., Syros Pharmaceuticals $130M on 2022-07-05; Diagonal Therapeutics $125M on 2026-01-08; Neumora Therapeutics $112M on 2022-10-11). The list is also heavily clustered in biotech: 19 of 30 companies are labeled Biotechnology (including multiple multi-decade pharma-style rounds such as Lyndra Therapeutics $101M on 2023-12-21 and Seismic Therapeutic $121M on 2023-12-04).
Temporally, rounds span from 2021-06-17 (Zus Health $34M) through 2026-06-18 (Portal $9M), with multiple biotech and data/health-adjacent deals recurring in 2022–2024. Several rounds lack a disclosed figure or a stated round type: 6 entries show “undisclosed” amounts (e.g., Via Separations on 2026-06-18; Extrasense Technologies on 2024-07-31), and 11 entries have “Series Unknown”/blank stage classifications (e.g., Clozex Medical on 2024-03-08; Fluent BioSciences on 2024-03-21).
Most recent rounds
30 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Watertown list, and how far above the rest is it?
Affini-T Therapeutics’ $175M venture - Series Unknown round (2022-03-22) is the largest disclosed amount in the table, and it substantially exceeds the next-highest disclosed figures such as Syros Pharmaceuticals ($130M on 2022-07-05) and Diagonal Therapeutics ($125M on 2026-01-08).
Which sectors are most over-represented among these 30 entries?
Biotechnology dominates with 19 of 30 companies labeled Biotechnology (e.g., Portal on 2026-06-18; Diagonal Therapeutics on 2026-01-08; Neumora Therapeutics on 2022-10-11). The next most frequent categories are single-digit counts such as Data and Analytics (The Cadmus Group on 2024-11-20; Adams Clinical on 2024-05-21) and Health Care (Clozex Medical on 2024-03-08; Zus Health on 2021-06-17).
How concentrated are rounds in the most recent time window shown?
The table’s most recent round date is 2026-06-18, with Portal ($9M) and Via Separations (undisclosed) both on that day. Beyond that, the newest 2026 entries also include Entact Bio ($10M) on 2026-06-03 and Diagonal Therapeutics ($125M) on 2026-01-08, indicating a notable pull into 2025–2026 versus earlier years like 2021-06-17 (Zus Health $34M).
What do the stage labels suggest about disclosure consistency here?
Round type is frequently not specified: 11 of 30 entries show “Series Unknown” or a blank stage classification (e.g., Via Separations on 2026-06-18; Fluent BioSciences on 2024-03-21). In parallel, 6 of 30 entries have “undisclosed” amounts even when a round date is given (e.g., Via Separations on 2026-06-18; Extrasense Technologies on 2024-07-31).
Are there extreme low-dollar outliers among disclosed amounts?
Yes: the smallest disclosed amount is Dynamo Software’s $100K private equity round on 2021-09-09, which is dramatically below the rest of the disclosed amounts in the table (e.g., SQZ Biotech’s $2M grant on 2022-03-21 and Dynamic Cell Therapies’ $1M on 2024-07-11).
Which biotech entries are clustered in the 2022–2024 window where many of the larger rounds appear?
Several of the larger disclosed biotech rounds fall within 2022–2024, including Syros Pharmaceuticals ($130M on 2022-07-05), Affini-T Therapeutics ($175M on 2022-03-22), Seismic Therapeutic ($121M on 2023-12-04), and Lyndra Therapeutics ($101M on 2023-12-21). That pattern contrasts with smaller biotech disclosed rounds scattered in later dates such as Dynamic Cell Therapies ($1M on 2024-07-11) and Portal ($9M on 2026-06-18).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.